BioAtla, Inc.

BCAB · OTC · United States

Share price · BCAB

$1.74-2.31 (-57.16%) 3M

no price since 28 Aug 2026

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BCAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Aug 2026-44.7%
  2. 14 Aug 2026-10.4%
  3. 7 Jul 2026-10.9%
  4. 20 Apr 2026+24.0%
  5. 26 Feb 2026+24.1%
  6. 2 Feb 2026-35.7%
  7. 31 Dec 2025-20.8%
  8. 21 Nov 2025-25.1%
  9. 18 Nov 2025+19.6%
  10. 17 Nov 2025+29.1%

Share of unusual movement by asset

For each asset, the share of BCAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ozuriftamab vedotin
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—67%

Assets

(3 total)
3Total Assets
0Approved
0Phase 3 / Filed
3Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 2
CTLA-4Biologic (subtype unspecified)
Non-Small Cell Lung CancerMelanoma
Phase 2
AXLAntibody–drug conjugate
Non-Small Cell Lung CancerSoft Tissue Sarcoma
Phase 2
ROR2Antibody–drug conjugate
Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$3.3M$1.5M—-$0.4M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$4.6M$2.0M$6.3M-$5.3M operating cash flowreport ↗
2025-Q3—$9.5M$8.3M$16M-$9.9M operating cash flowreport ↗
2025-Q2—$14M$18M$19M-$14M operating cash flowreport ↗
2025-Q1—$12M$32M$15M-$16M operating cash flowreport ↗
2024-Q3—$16M$57M$11M-$5.1M operating cash flowreport ↗
2024-Q2—$16M$62M$21M-$19M operating cash flowreport ↗
2024-Q1—$19M$81M$23M-$31M operating cash flowreport ↗
2023-Q3$0$28M$141M$33M-$27M operating cash flowreport ↗
2023-Q2$0$31M$169M$36M-$24M operating cash flowreport ↗
2023-Q1$0$22M$193M$27M-$23M operating cash flowreport ↗
2022-Q3$0$20M$178M$26M-$24M operating cash flowreport ↗
2022-Q2$0$21M$202M$29M-$17M operating cash flowreport ↗
2022-Q1$0$17M$219M$24M-$25M operating cash flowreport ↗
2021-Q3—$17M$270M$23M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$44M$7.1M$15M-$48M operating cash flowreport ↗

BioAtla reported collaboration and other revenue of $2.0M for the full year 2025, down from $11.0M in 2024, with R&D spend of $43.57M, down 31.0% YoY from $63.1M. Cash and cash equivalents stood at $7.1M, and the company reported a net loss of $59.6M, compared to a net loss of $69.8M in 2024.

Management initiated a formal process to explore strategic options, including asset sales, licensing, or partnerships, and engaged Tungsten Advisors as exclusive financial advisor, while implementing a workforce reduction and other cost-containment measures. The company expects R&D and G&A expenses to decline in 2026 and continues to conduct the Phase 1 study of BA3182 in adenocarcinomas, with ozuriftamab vedotin in Phase 3 for OPSCC and other candidates in earlier-stage development.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$63M$49M$17M-$72M operating cash flowreport ↗
2023-FY—$104M$111M$31M-$104M operating cash flowreport ↗
2022-FY—$79M$216M$27M-$90M operating cash flowreport ↗
2021-FY$0.3M$58M$245M$24M-$62M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-31Vasquez Christian · Chief Financial OfficerTax withholding71$1.69$120Form 4
2026-08-31SHORT JAY M PHD · director, Chief Executive OfficerTax withholding259$1.69$438Form 4
2026-08-31Sievers Eric · Chief Medical OfficerTax withholding134$1.69$226Form 4
2026-05-31Sievers Eric · Chief Medical OfficerTax withholding134$3.93$527Form 4
2026-05-31SHORT JAY M PHD · director, Chief Executive OfficerTax withholding259$3.93$1KForm 4
2026-05-31Vasquez Christian · Chief Financial OfficerTax withholding82$3.93$322Form 4
2026-03-12SHORT JAY M PHD · director, Chief Executive OfficerTax withholding639$0.17$107Form 4
2026-03-11Sievers Eric · Chief Medical OfficerTax withholding360$0.17$61Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2 reporting institutions held 0.3M shares ($46K).

#InstitutionSharesValue
1MARSHALL WACE, LLP277,630$44K
2SBI Securities Co., Ltd.11,124$2K